FindTrial
Sign In

Phase III Study to Evaluate the Efficacy and Safety of AD-209

A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06348576
Enrollment
280
Registered
2024-04-04
Start date
2024-05-20
Completion date
2025-02-28
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension,Essential

Brief summary

The purpose of this study is to evaluate the efficacy and safety of AD-209

Detailed description

Condition or disease : hypertension

Interventions

DRUGAD-209

PO, Once daily(QD), 8weeks

DRUGAD-2091

PO, Once daily(QD), 8weeks

DRUGAD-209 Placebo

PO, Once daily(QD), 8weeks

DRUGAD-2091 Placebo

PO, Once daily(QD), 8weeks

Sponsors

Addpharma Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Other inclusions applied

Exclusion criteria

* Orthostatic hypotension with symptom * Other exclusions applied

Design outcomes

Primary

MeasureTime frameDescription
Change rate of MSSBPBaseline, Week 8Change from baseline in mean sitting systolic blood pressure

Countries

South Korea

Contacts

Primary ContactKyung Tae Kim, D.V.M
ktkim@addpharma.co.kr82-031-891-5661
Backup ContactChang Gyu Park, M.D., Ph.D

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026